621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This two-year study is crucial for understanding the long-term effectiveness and safety of Semaglutide as a treatment for overweight and obesity. If the results demonstrate sustained weight loss and a favorable safety…
This multi-national trial is crucial for understanding the comparative effectiveness of two prominent classes of Type 2 Diabetes medications when added to standard metformin therapy. The findings, once published, will…
Understanding how liver function affects oral semaglutide's pharmacokinetics is crucial for dose adjustments and patient safety, especially given the widespread use of GLP-1 receptor agonists for type 2 diabetes. The …
This study holds significant promise for addressing a critical unmet medical need: effective treatment for early-onset, treatment-resistant obesity in young adults. If successful, the RESETTLE Study could establish se…
The discontinuation of GLP-1 agonists often leads to weight regain and a return of metabolic challenges, including elevated triglycerides, which are risk factors for cardiovascular disease. If RDX-002 proves effective…
This SemaGBA system dynamics model provides a crucial mechanistic understanding of how semaglutide orchestrates its effects on the gut-brain axis to promote weight loss. By simulating complex biological interactions, …
This study provides crucial real-world evidence supporting the safe and effective use of semaglutide in a highly vulnerable patient group where therapeutic options are often limited and complex. The observed improveme…
This research provides compelling evidence for semaglutide's neuroprotective potential beyond its well-known glucose-lowering effects, highlighting a novel mechanism involving the gut-brain axis and sphingolipid metab…
These findings provide critical clinical guidance, underscoring that semaglutide's profound cardiovascular benefits are robust and complementary to, rather than dependent on, traditional antiplatelet therapy with aspi…
This research highlights the distinct advantages of metabolic bariatric surgery for improving liver health outcomes in patients with co-existing MASLD and T2D, potentially offering a more comprehensive solution for th…
This groundbreaking research underscores the potential of Semaglutide as a multifaceted therapeutic agent, extending its benefits beyond glycemic control and weight management to include significant liver protection. …
These meticulously developed guidelines are profoundly important for enhancing patient safety and optimizing long-term oral health outcomes for the rapidly expanding population of individuals prescribed semaglutide fo…
This research provides compelling evidence that GLP-1 receptor agonists could represent a novel and effective strategy for smoking cessation. The observed reductions in nicotine seeking and withdrawal symptoms, couple…
This network meta-analysis provides crucial evidence that could significantly impact clinical guidelines for managing Type 2 Diabetes patients with high cardiovascular risk. The identification of specific GLP-1 recept…
This research provides robust real-world evidence confirming the effectiveness of GLP-1 therapies in a diverse Middle Eastern population, mirroring results from controlled clinical trials. The observed significant red…
This comprehensive 'Trial Watch' is crucial for understanding the evolving landscape of MASH treatment and identifying the most promising therapeutic avenues. It provides invaluable insights for clinicians, researcher…
This case series provides crucial preliminary evidence suggesting that GLP-1 RAs can be a safe and effective therapeutic option for weight management in older adults, challenging previous hesitations regarding their u…
This research highlights the critical need for a more personalized approach to semaglutide therapy, moving beyond average treatment effects. Identifying predictors for suboptimal response could enable clinicians to ta…
This case, if substantiated by detailed clinical data, suggests that Semaglutide could represent a novel and effective therapeutic option for patients with Ulcerative Colitis, particularly those who also suffer from o…
This case report is highly significant given the rapidly expanding use of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, including its off-label use for weight loss. This finding suggests a potential…
This case report highlights a potential novel therapeutic avenue for ulcerative colitis, suggesting that GLP-1 RAs like semaglutide might offer benefits beyond metabolic control. The observed symptomatic remission and…
This study provides compelling real-world evidence that combining GLP-1 therapy with digital coaching is a highly effective and scalable strategy for obesity management, particularly in diverse populations. The high r…
This case report highlights a novel and important consideration for healthcare providers prescribing semaglutide to patients with lower limb amputations. The rapid and significant weight loss induced by GLP-1 agonists…
The successful completion of this trial could lead to the availability of a new semaglutide injection, potentially increasing access and offering more treatment options for Type 2 Diabetes patients. If the investigati…
This retrospective analysis holds significant potential to optimize current clinical treatment strategies for metabolic syndrome. By comparing the real-world effectiveness of established interventions like semaglutide…
This research holds significant promise for optimizing pediatric obesity treatment strategies, potentially leading to more accessible and sustainable interventions for a vulnerable population. The findings could redef…
This large-scale, pragmatic trial is crucial because it directly compares two leading therapeutic strategies for Type 2 Diabetes patients at high risk for cardiovascular and kidney complications. The findings could pr…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
Finding effective strategies to prevent weight regain after discontinuing GLP-1 agonists is critically important for long-term obesity management and patient well-being. This trial could provide evidence for new stand…
This groundbreaking GLP-1 brain atlas provides a foundational neuroanatomical map, offering unprecedented insights into the diverse physiological roles of GLP-1 beyond its well-known glucose-lowering effects. By preci…
This comprehensive synthesis underscores the critical role of inflammation as a shared, actionable therapeutic target for both cardiovascular disease and diabetes mellitus, moving beyond traditional single-disease app…
This study provides novel mechanistic insights into how Semaglutide exerts its therapeutic effects beyond simply delaying gastric emptying. Understanding these specific changes in gastric electrical activity could opt…
This study provides crucial evidence that a new, potentially more accessible semaglutide formulation can offer comparable efficacy and safety to the established reference drug for weight management. This could signifi…
This study underscores the immense public health implications of expanding semaglutide indications to include fibrotic MASH. It identifies a large, distinct, and currently underserved population with severe liver dise…
This study provides crucial real-world evidence that polyethylene glycol loxenatide is a highly effective and safe treatment option for Type 2 diabetes, offering comparable benefits to the widely used semaglutide. The…
This research highlights a novel therapeutic potential for Semaglutide beyond its established roles in diabetes and obesity, suggesting it could directly address cardiovascular complications associated with sarcopenia…
This study highlights that oral semaglutide not only manages blood glucose but also significantly reduces diabetes-related distress, thereby improving patient quality of life and potentially enhancing adherence to tre…
The analysis revealed a consistent and significant deficiency in the use of objective functional measures across studies investigating semaglutide in frail HFpEF populations. Many existing reports relied heavily on su…
This research provides crucial insights into the genetic underpinnings of GLP-1 RA response, paving the way for personalized treatment strategies. By identifying individuals most likely to benefit or experience advers…
This real-world study provides crucial evidence supporting the clinical benefit and safety of escalating once-weekly semaglutide from 0.5 mg to 1.0 mg in patients with Type 2 Diabetes. The significant improvements in …